<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884673</url>
  </required_header>
  <id_info>
    <org_study_id>V2.0-20181215</org_study_id>
    <nct_id>NCT03884673</nct_id>
  </id_info>
  <brief_title>Dolutegravir Plus Lamivudine Simplified Therapy</brief_title>
  <official_title>Real World Study: Dolutegravir Plus Lamivudine Simplified Therapy in Treatment Experienced HIV-1 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou 8th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Guilin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Longtan hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth Peopleâ€™s Hospital of Nanning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Kunming</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan AIDS Care Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meng Chao Hepatobiliary Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou 8th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dolutegravir (DTG) is one type of integrase inhibitor, lamivudine (3TC) is one type of
      reverse transcriptase inhibitor, both of which are HIV medicine prevents HIV from
      self-multiplying, reduces the viral load. The data of the existing randomized controlled
      clinical studies show that the simplified two-drug DTG-based regimen is similar to the
      three-drug regimen in terms of efficacy, but there are no relevant data and reports on the
      efficacy and safety of DTG+3TC in HIV-infected patients in China so far. This project aims to
      explore the efficacy and safety of the DTG + 3TC regimen for HIV-infected patients in real
      clinical environment, to guide clinical application, and to provide a theoretical basis for
      the selection of simplified schemes for the formulation of guidelines.

      This study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG,
      Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and
      well-tolerated treatment for HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, multicentered, single-arm and phase IV clinical trial. 300
      HIV-infected patients who received simplified treatment regimen (50mg DTG+ 400mg 3TC, oral,
      qd) were selected to observe the treatment efficacy. At week 24, 36, 48 and 96, the rate of
      viral suppression and CD4 cell count were calculated against baseline. In addition, the
      safety and drug compliance were also monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Virus suppression rate</measure>
    <time_frame>96 weeks</time_frame>
    <description>ratio of HIV RNA &lt; 50 copies/mL at 48 and 96 weeks of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>96 weeks</time_frame>
    <description>Rate of adverse events reported during the observational period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The immunological ability (CD4+)</measure>
    <time_frame>96 weeks</time_frame>
    <description>CD4 cell count (baseline to 48 weeks and 96 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>96 weeks</time_frame>
    <description>To explicit the number of people who have completed the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The immunological ability (CD8+)</measure>
    <time_frame>96 weeks</time_frame>
    <description>CD4 +/ CD8 + ratio (baseline to 48 weeks and 96 weeks)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>DTG+3TC</arm_group_label>
    <description>These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG+ 3TC</intervention_name>
    <description>It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.</description>
    <arm_group_label>DTG+3TC</arm_group_label>
    <other_name>A simplified therapy regimen</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are prescribed to take the simplified therapy regimen (DTG+ 3TC) because they
        are unable to tolerate the side-effect of or are not fit for the first-line free regimen in
        China, for example renal failure or osteoporosis, according to clinical judgment, no matter
        of the HIV-RNA viral loads and CD4 cell counts.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age (&gt; 18 years), male and female;

          2. HIV-1 infected;

          3. Using a standard three-drug-based regimen for at least 24 weeks. Based on clinical
             decision making* decide if patients can be treated with the DTG+3TC simplified scheme
             for a variety of reasons, such as (but not limited to): patients cannot tolerate the
             conventional three-drug treatment scheme, renal insufficiency, osteoporosis, bone
             marrow suppression and for other reasons patients cannot use the conventional
             three-drug treatment scheme;

          4. Initial HIV-1 RNA viral load and CD4 cell count were unlimited.

          5. CD4 can be monitored at least three times in the first year (including baseline, 24
             weeks of treatment and 48 weeks of treatment). After the first year, CD4 can be
             detected at least once every six months.

          6. State Informed Consent for Free Treatment has been signed;

          7. Good compliance and signing Informed Consent

        (* Reference criteria: Refer to APSIRE study, creatinine clearance rate (&gt; 50 mL/min), no
        DTG/3TC allergy history, HBsAg negative, no chronic liver disease, no severe liver damage,
        no pregnancy during the study)

        Exclusion Criteria:

          1. Has participated in other clinical trials of HIV vaccine or other drug trials in the
             past three months;

          2. Researchers decide if patients could/not complete the scheduled follow-up (factors to
             consider such as weak, poor compliance, etc.).

          3. Has a clear history of DTG or 3TC allergy;

          4. HBsAg and/or HBV-DNA positive;

          5. Pregnancy during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiping Cai, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou 8th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linghua Li, PhD</last_name>
    <phone>020-83710825</phone>
    <email>llheliza@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weiping Cai, Bachelor</last_name>
    <phone>020-83710825</phone>
    <email>gz8hcwp@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou 8th People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linghua Li, PhD</last_name>
      <phone>020-83710825</phone>
      <email>llheliza@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.</citation>
    <PMID>30420123</PMID>
  </reference>
  <reference>
    <citation>Cahn P, RolÃ³n MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017 May 9;20(1):21678. doi: 10.7448/IAS.20.01.21678.</citation>
    <PMID>28537061</PMID>
  </reference>
  <reference>
    <citation>Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA &lt;500000 Copies/mL. Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.</citation>
    <PMID>29253097</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou 8th People's Hospital</investigator_affiliation>
    <investigator_full_name>Linghua LI</investigator_full_name>
    <investigator_title>Vice Chief physician</investigator_title>
  </responsible_party>
  <keyword>DTG + 3TC Simplified Therapy</keyword>
  <keyword>Simplified Therapy Regimen</keyword>
  <keyword>Real World Study</keyword>
  <keyword>HIV-1-infected patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

